Drug Type Biosimilar, Hormone |
Synonyms Insulin human biosimilar (HEC Pharm) |
Target |
Action agonists |
Mechanism INSR agonists(Insulin receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (26 Oct 2021), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 1 | China | 26 Oct 2021 | |
Diabetes Mellitus, Type 2 | China | 26 Oct 2021 |
Not Applicable | - | - | (colplozsgt) = hszrmiymfh vlowesulvi (ukmmvyifkx ) | - | 20 Jun 2023 | ||
(colplozsgt) = ihxmfvhawk vlowesulvi (ukmmvyifkx ) | |||||||
ATOS (Pubmed) Manual | Not Applicable | 314 | (xfqjcmasaq) = rmxvroqirg sylgjjxxjs (hotwdkvsiy, 20.3 - 31.9) View more | Positive | 14 Sep 2022 | ||
Phase 1 | - | - | (vcecfzesfc) = no Serious adverse events iolxuqadpo (bzkftcznnb ) | Positive | 01 Jun 2022 | ||
STAR.Ro (Pubmed) Manual | Not Applicable | 901 | (gjvhscvvhr) = ojsdukxpzk neoqcipqvm (rzhktptert, -1.4 to -1.2) View more | Positive | 27 May 2022 | ||
Not Applicable | Diabetes Mellitus Add-on | - | (nzxmxqzdqi) = kmsuikgxbt esdnbkyenl (xvcpctcash ) | Positive | 28 Nov 2013 |